Ocugen, Inc. (OCGN) is a biopharmaceutical company based in the United States with a focus on discovering, developing, and commercializing transformative therapies for rare diseases and blindness. Established in 2013, the company's primary mission is to address the unmet medical needs of patients with debilitating eye diseases that significantly impact their quality of life.
Ocugen's groundbreaking research and innovative gene therapy platform are at the heart of the company's ambition. Their research pipeline includes potential treatments for diseases like age-related macular degeneration and diabetic macular edema. The company is making significant strides in applying novel biological insights to produce new solutions that could change patients' lives forever.
One of Ocugen's most promising projects is COVAXIN, a coronavirus vaccine that received emergency use authorization in India. COVAXIN is a whole-virion inactivated COVID-19 vaccine manufactured by Bharat Biotech in partnership with the Indian Council of Medical Research – National Institute of Virology (ICMR-NIV). Ocugen is collaborating with Bharat Biotech to introduce COVAXIN to the U.S. market.
Ocugen's pioneering approach, along with their journey to provide innovative life-changing treatments, has earned the company recognition within the biopharmaceutical industry and beyond. Furthermore, through strong collaborations and partnerships, Ocugen is able to access state-of-the-art technology and world-class expertise, which bolsters its ability to meet its ambitious vision of helping patients with unmet medical needs.
Despite the extensive challenges of drug development, Ocugen continually strives to deliver radically improved treatments to patients who currently have few or no options. It's this dedicated commitment to making a difference that positions Ocugen as a leader in the realm of biopharmaceutical innovation.
The company is listed on the NASDAQ under the symbol "OCGN" and continues to make waves in the medical research community. Despite the inherent risks and uncertainties associated with pharmaceutical research, Ocugen remains steadfast in its pursuit, leveraging cutting-edge science and technology, to enhance and expand its product portfolio, thereby paving the way toward a promising future for those affected by serious diseases and blindness. It is a company truly driven by its mission to improve capability and continuity of care.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Ocugen Inc. (OCGN) stock fell 4.15% to $0.74 on Thursday, ending a two-day winning streak. This decline occurred during a generally challenging trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average also experiencing drops.
Ocugen Inc. (OCGN) stock increased by 2.51% to $0.78 on Wednesday, outperforming the broader market. The S&P 500 Index rose 0.28% and the Dow Jones Industrial Average rose 0.19% on the same day. This marks the second consecutive day of gains for Ocugen.
Ocugen Inc. (OCGN) stock decreased by 4.23% to $0.71 on Monday, marking its third consecutive day of losses. This occurred despite an overall positive trading session for the market, with the S&P 500 Index rising 0.70% and the Dow Jones Industrial Average increasing 0.28%.
Ocugen Inc. (OCGN) stock declined 3.08% to $0.79 on Thursday, ending a three-day winning streak. This occurred during a mixed trading session where the Dow Jones Industrial Average saw a slight gain, while the S&P 500 Index experienced a decline.
Ocugen, a biotechnology company based in Malvern, Pennsylvania, has granted exclusive rights to Roots Pharmaceutical for its investigational retinitis pigmentosa (RP) treatment, OCU400, across the Middle East and North Africa (MENA). This licensing agreement aims to address the high prevalence of RP in the MENA region, with Ocugen set to receive an upfront license fee, potential development milestones, and royalties on net sales. The modifier gene therapy, OCU400, is currently in a Phase 3 clinical trial, with topline data expected in Q1 2027.
Ocugen Inc. (OCGN) stock increased by 3.20% to $0.81 on Tuesday, outperforming the broader market. The S&P 500 Index rose 0.28%, and the Dow Jones Industrial Average gained 1.02% on the same day. This marks the second consecutive day of gains for Ocugen's stock.